| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H30O3 |
| Molecular Weight | 354.4825 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 4 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)\C=C(C)\C=C\C=C(C)\C=C\C1=C(C)C=C(OC)C(C)=C1C
InChI
InChIKey=HQMNCQVAMBCHCO-DJRRULDNSA-N
InChI=1S/C23H30O3/c1-8-26-23(24)14-17(3)11-9-10-16(2)12-13-21-18(4)15-22(25-7)20(6)19(21)5/h9-15H,8H2,1-7H3/b11-9+,13-12+,16-10+,17-14+
| Molecular Formula | C23H30O3 |
| Molecular Weight | 354.4825 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 4 |
| Optical Activity | NONE |
Etretinate (trade name Tegison) is a medication developed by Hoffmann–La Roche that was approved by the FDA in 1986 to treat severe psoriasis. It is a second-generation retinoid. It was subsequently removed from the Canadian market in 1996 and the United States market in 1998 due to the high risk of birth defects. Etretinate remains on the market in Japan as Tigason. The mechanism of action of etretinate is still incompletely understood although, like retinoic acid, it is thought to interfere with the terminal differentiation of keratinocytes. Etretinate activates retinoid receptors, causing an induction of cell differentiation, inhibition of cell proliferation, and inhibition of tissue infiltration by inflammatory cells.
CNS Activity
Originator
Approval Year
Doses
AEs
Sourcing
PubMed
Patents
Sample Use Guides
Initial: 0.75 mg to 1 mg per kg of body weight per day in divided doses. Maintenance: 0.5 to 0.75 mg per kg of body weight per day may be initiated after initial response, generally after 8 to 16 weeks of therapy.
Usual adult prescribing limits 1.5 mg per kg of body weight per day.
Route of Administration:
Oral
Erythrocytes were isolated from fresh blood by centrifugation. Etretinate (as DMSO solution) was added to the suspensions of erythrocytes. The final concentration of etretinate was 1.4nM. Erythrocyte suspensions were incubated for 30 min at 370C. After treatment with etretinate, a significant increase in erythrocyte membrane fluidity and in antioxidant activity as well as a decrease in lipid peroxidation were observed in erythrocytes from patients.
